Interleukin 10 gene promoter polymorphism and risk of diffuse large B cell lymphoma (DLBCL)

• Main Authors: Roba M. Talaat, Amal M. Abdel-Aziz, Eman A. El-Maadawy, Naser Abdel-Bary
• Format: Article
• Language: English
• Published: SpringerOpen 2014-01-01
• Series: Egyptian Journal of Medical Human Genetics
• Subjects: NHL; DLBCL; SNP; IL-10; ELISA
• Online Access: http://www.sciencedirect.com/science/article/pii/S1110863013000633

Purpose: Given the importance of understanding the genetic variations involved in the pathogenesis of non-Hodgkin’s lymphoma (NHL), this work was designed to study the impact of IL-10 (−1082 G/A; rs1800896 and −819 C/T; rs1800871) gene promoter polymorphism on susceptibility of Egyptians to diffuse large B cell lymphoma (DLBCL); the major type of NHL. To the best of our knowledge, this study is the first one that examines IL-10 promoter polymorphism in DLBCL in Egyptians. Methods: Genotyping polymorphism is performed using sequence-specific primers polymerase chain reaction (SSP-PCR) in 100 Egyptian DLBCL patients and 119 normal controls. Circulating plasma levels of IL-10 were measured using Enzyme-linked immunosorbent assay (ELISA). Results: Insignificant change in IL-10 (−1082 and −819) genotypes was recorded. Although A allele is slightly decreased in DLBCL patients, it did not reach statistical significance. GT haplotype was significantly elevated (P < 0.05) in NHL patients. A significant linkage disequilibrium between the −1082 and −819 SNPs with D′ = 0.596 and r2 = 0.1032 (P < 0.001) was demonstrated. Significantly increased plasma IL-10 (P < 0.01) was found which is positively correlated (r = 0.307; P < 0.01) with the disease. Conclusions: Taken together, our findings demonstrated that IL-10 promoter gene polymorphism (−1082 and −819) may not have an influence on the clinical outcome of DLBCL, especially in terms of overall secretion level. Further investigations of other cytokine gene polymorphisms will lead to a better understanding of the disease’s biological background.